Symbols / ARMP
ARMP Chart
About
Armata Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company that focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has research collaboration agreement with Merck Sharp & Dohme Corp. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is based in Los Angeles, California. Armata Pharmaceuticals, Inc. operates as a subsidiary of Innoviva, Inc.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 439.68M |
| Enterprise Value | 593.80M | Income | -46.90M | Sales | 5.05M |
| Book/sh | -2.64 | Cash/sh | 0.41 | Dividend Yield | — |
| Payout | 0.00% | Employees | 60 | IPO | — |
| P/E | — | Forward P/E | -7.69 | PEG | — |
| P/S | 87.00 | P/B | -4.58 | P/C | — |
| EV/EBITDA | -18.64 | EV/Sales | 117.49 | Quick Ratio | 0.11 |
| Current Ratio | 0.12 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -1.66 | EPS next Y | -1.57 | EPS Growth | — |
| Revenue Growth | -61.00% | Earnings | 2026-03-18 | ROA | -22.20% |
| ROE | — | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | -6.71% | Profit Margin | 0.00% | Shs Outstand | 36.41M |
| Shs Float | 11.03M | Short Float | 2.54% | Short Ratio | 4.99 |
| Short Interest | — | 52W High | 16.34 | 52W Low | 0.90 |
| Beta | 1.42 | Avg Volume | 47.79K | Volume | 17.26K |
| Target Price | $15.00 | Recom | Strong_buy | Prev Close | $11.40 |
| Price | $12.08 | Change | 5.94% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$15.00
Mean price target
2. Current target
$12.08
Latest analyst target
3. DCF / Fair value
$-12.47
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$12.08
Low
$15.00
High
$15.00
Mean
$15.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2026-02-23 | main | HC Wainwright & Co. | Buy → Buy | $15 |
| 2026-01-05 | init | Jones Trading | — → Buy | $15 |
| 2025-05-19 | main | HC Wainwright & Co. | Buy → Buy | $9 |
| 2024-12-19 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-11-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-07-11 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-05-08 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2024-03-22 | main | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-08-14 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-05-12 | reit | HC Wainwright & Co. | Buy → Buy | $7 |
| 2023-03-17 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2023-03-07 | reit | HC Wainwright & Co. | — → Buy | $7 |
| 2021-03-22 | main | HC Wainwright & Co. | — → Buy | $7 |
| 2020-05-15 | reit | HC Wainwright & Co. | — → Buy | $5 |
| 2020-03-20 | reit | HC Wainwright & Co. | — → Buy | $9 |
| 2020-02-06 | init | Maxim Group | — → Buy | $8 |
| 2019-06-19 | init | Ladenburg Thalmann | — → Buy | $9 |
- Armata Pharmaceuticals (ARMP) Price Target Increased by 25.00% to 15.30 - Nasdaq Wed, 25 Feb 2026 00
- FDA grants special status to phage therapy for dangerous staph infections - Stock Titan Mon, 23 Feb 2026 12
- ARMP: HC Wainwright & Co. Raises Price Target to $15 | ARMP Stoc - GuruFocus Mon, 23 Feb 2026 16
- Armata Pharmaceuticals stock gains on FDA designation By Investing.com - Investing.com Nigeria Mon, 23 Feb 2026 13
- Armata Pharmaceuticals (ARMP) Surges 103.2%: Is This an Indication of Further Gains? - Yahoo Finance hu, 23 Oct 2025 07
- Armata Pharmaceuticals Announces Third Quarter 2025 Results and Provides Corporate Update - PR Newswire Wed, 12 Nov 2025 08
- Armata surges on mid-stage trial data for antibacterial agent - Seeking Alpha Wed, 22 Oct 2025 07
- Here’s Why Armata Pharmaceuticals Stock (ARMP) Exploded 300% Today - TipRanks Wed, 22 Oct 2025 07
- A Look at Armata Pharmaceuticals’s Valuation After Positive Phase 2a Bacteriophage Trial Results (ARMP) - simplywall.st hu, 23 Oct 2025 07
- H.C. Wainwright lowers Armata Pharmaceuticals stock price target to $15 - Investing.com ue, 24 Feb 2026 12
- Are Medical Stocks Lagging Armata Pharmaceuticals (ARMP) This Year? - Yahoo Finance Mon, 06 Oct 2025 07
- Armata Pharmaceuticals (ARMP) Receives FDA Designation for AP-SA - GuruFocus Mon, 23 Feb 2026 13
- Antibiotic-resistant Staphylococcus aureus study moves to Armata Phase 3 - Stock Titan ue, 13 Jan 2026 08
- Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance Wed, 12 Nov 2025 08
- Armata Pharmaceuticals (ARMP) Shares Surge by 19% - GuruFocus Wed, 22 Oct 2025 07
Insider Transactions
| Date | Shares | Value | Url | Text | Insider | Position | Transaction | Start Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 60000 | — | — | Stock Award(Grant) at price 0.00 per share. | BIRX DEBORAH L. | Chief Executive Officer | — | 2024-03-14 00:00:00 | D |
| 1 | 10000 | — | — | Stock Award(Grant) at price 0.00 per share. | RYCHLIK RICHARD | Officer | — | 2024-03-14 00:00:00 | D |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | 0.00 |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.00 |
| NormalizedEBITDA | -9.02M | -61.58M | -36.02M | -22.65M |
| TotalUnusualItems | 2.17M | -3.86M | 0.00 | 726.00K |
| TotalUnusualItemsExcludingGoodwill | 2.17M | -3.86M | 0.00 | 726.00K |
| NetIncomeFromContinuingOperationNetMinorityInterest | -18.92M | -69.05M | -36.92M | -23.16M |
| ReconciledDepreciation | 1.32M | 972.00K | 892.00K | 1.17M |
| EBITDA | -6.85M | -65.45M | -36.02M | -21.92M |
| EBIT | -8.17M | -66.42M | -36.92M | -23.09M |
| NetInterestIncome | -10.04M | -2.45M | 29.00K | -59.00K |
| InterestExpense | 10.74M | 2.63M | 0.00 | 64.00K |
| InterestIncome | 697.00K | 179.00K | 29.00K | 5.00K |
| NormalizedIncome | -21.08M | -65.18M | -36.92M | -23.88M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -18.92M | -69.05M | -36.92M | -23.16M |
| TotalExpenses | 42.44M | 40.89M | 36.95M | 23.82M |
| TotalOperatingIncomeAsReported | -42.44M | -40.89M | -36.95M | -23.82M |
| DilutedAverageShares | 59.06M | 36.08M | 34.29M | 24.10M |
| BasicAverageShares | 36.16M | 36.08M | 34.29M | 24.10M |
| DilutedEPS | -0.89 | -1.91 | -1.08 | -0.96 |
| BasicEPS | -0.52 | -1.91 | -1.08 | -0.96 |
| DilutedNIAvailtoComStockholders | -18.92M | -69.05M | -36.92M | -23.16M |
| NetIncomeCommonStockholders | -18.92M | -69.05M | -36.92M | -23.16M |
| NetIncome | -18.92M | -69.05M | -36.92M | -23.16M |
| NetIncomeIncludingNoncontrollingInterests | -18.92M | -69.05M | -36.92M | -23.16M |
| NetIncomeContinuousOperations | -18.92M | -69.05M | -36.92M | -23.16M |
| PretaxIncome | -18.92M | -69.05M | -36.92M | -23.16M |
| OtherIncomeExpense | 33.56M | -25.71M | 726.00K | |
| OtherNonOperatingIncomeExpenses | 31.40M | -21.84M | ||
| SpecialIncomeCharges | 2.17M | -3.86M | 0.00 | 726.00K |
| OtherSpecialCharges | -2.17M | 3.86M | -726.00K | |
| NetNonOperatingInterestIncomeExpense | -10.04M | -2.45M | 29.00K | -59.00K |
| InterestExpenseNonOperating | 10.74M | 2.63M | 0.00 | 64.00K |
| InterestIncomeNonOperating | 697.00K | 179.00K | 29.00K | 5.00K |
| OperatingIncome | -42.44M | -40.89M | -36.95M | -23.82M |
| OperatingExpense | 42.44M | 40.89M | 36.95M | 23.82M |
| OtherOperatingExpenses | -5.17M | -4.53M | -5.51M | -4.47M |
| ResearchAndDevelopment | 34.43M | 33.77M | 35.02M | 20.02M |
| SellingGeneralAndAdministration | 13.18M | 11.65M | 7.44M | 8.28M |
| GeneralAndAdministrativeExpense | 13.18M | 11.65M | 7.44M | 8.28M |
| OtherGandA | 13.18M | 11.65M | 7.44M | 8.28M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| OrdinarySharesNumber | 36.18M | 36.12M | 36.14M | 27.11M |
| ShareIssued | 36.18M | 36.12M | 36.14M | 27.11M |
| NetDebt | 85.10M | 68.78M | ||
| TotalDebt | 126.52M | 120.37M | 48.81M | 37.99M |
| TangibleBookValue | -61.77M | -45.81M | 22.33M | 11.65M |
| InvestedCapital | 46.37M | 50.24M | 36.08M | 25.40M |
| WorkingCapital | -36.94M | 2.69M | 2.17M | 10.18M |
| NetTangibleAssets | -61.77M | -45.81M | 22.33M | 11.65M |
| CapitalLeaseObligations | 32.12M | 38.06M | 48.81M | 37.99M |
| CommonStockEquity | -48.02M | -32.06M | 36.08M | 25.40M |
| TotalCapitalization | 7.42M | 50.24M | 36.08M | 25.40M |
| TotalEquityGrossMinorityInterest | -48.02M | -32.06M | 36.08M | 25.40M |
| StockholdersEquity | -48.02M | -32.06M | 36.08M | 25.40M |
| RetainedEarnings | -327.74M | -308.82M | -239.77M | -202.86M |
| AdditionalPaidInCapital | 279.35M | 276.39M | 275.49M | 227.98M |
| CapitalStock | 362.00K | 361.00K | 361.00K | 271.00K |
| CommonStock | 362.00K | 361.00K | 361.00K | 271.00K |
| TotalLiabilitiesNetMinorityInterest | 134.46M | 130.43M | 59.75M | 44.37M |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 86.21M | 113.97M | 34.88M | 39.56M |
| NonCurrentDeferredLiabilities | 3.08M | 3.08M | 3.08M | 3.08M |
| NonCurrentDeferredTaxesLiabilities | 3.08M | 3.08M | 3.08M | 3.08M |
| LongTermDebtAndCapitalLeaseObligation | 83.13M | 110.89M | 31.80M | 36.48M |
| LongTermCapitalLeaseObligation | 27.69M | 28.58M | 31.80M | 36.48M |
| LongTermDebt | 55.44M | 82.31M | ||
| CurrentLiabilities | 48.25M | 16.46M | 24.87M | 4.81M |
| OtherCurrentLiabilities | 529.00K | 523.00K | ||
| CurrentDeferredLiabilities | 0.00 | |||
| CurrentDebtAndCapitalLeaseObligation | 43.38M | 9.48M | 17.01M | 1.51M |
| CurrentCapitalLeaseObligation | 4.43M | 9.48M | 17.01M | 1.51M |
| CurrentDebt | 38.95M | |||
| OtherCurrentBorrowings | 38.95M | |||
| CurrentNotesPayable | 0.00 | |||
| PensionandOtherPostRetirementBenefitPlansCurrent | 2.28M | 768.00K | 1.83M | 1.03M |
| PayablesAndAccruedExpenses | 2.06M | 5.69M | 6.03M | 2.27M |
| CurrentAccruedExpenses | 1.29M | 4.10M | 4.36M | 1.13M |
| Payables | 766.00K | 1.58M | 1.68M | 1.14M |
| AccountsPayable | 766.00K | 1.58M | 1.68M | 1.14M |
| TotalAssets | 86.44M | 98.36M | 95.83M | 69.77M |
| TotalNonCurrentAssets | 75.13M | 79.21M | 68.79M | 54.77M |
| OtherNonCurrentAssets | 6.46M | 8.19M | 8.39M | 2.96M |
| GoodwillAndOtherIntangibleAssets | 13.75M | 13.75M | 13.75M | 13.75M |
| OtherIntangibleAssets | 10.26M | 10.26M | 10.26M | 10.26M |
| Goodwill | 3.49M | 3.49M | 3.49M | 3.49M |
| NetPPE | 54.93M | 57.28M | 46.65M | 38.07M |
| AccumulatedDepreciation | -13.15M | -11.82M | -11.10M | -10.22M |
| GrossPPE | 68.07M | 69.10M | 57.76M | 48.30M |
| Leases | 3.80M | 3.45M | 3.45M | 3.42M |
| OtherProperties | 63.00M | 64.39M | 53.04M | 43.61M |
| MachineryFurnitureEquipment | 1.27M | 1.25M | 1.27M | 1.27M |
| Properties | 0.00 | 0.00 | 0.00 | 0.00 |
| CurrentAssets | 11.31M | 19.15M | 27.05M | 14.99M |
| OtherCurrentAssets | 1.27M | 2.27M | 3.66M | 1.72M |
| PrepaidAssets | 1.72M | |||
| Receivables | 744.00K | 3.36M | 8.53M | 2.99M |
| OtherReceivables | 744.00K | 3.36M | 8.53M | 2.99M |
| CashCashEquivalentsAndShortTermInvestments | 9.29M | 13.52M | 14.85M | 10.29M |
| CashAndCashEquivalents | 9.29M | 13.52M | 14.85M | 10.29M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -39.43M | -55.57M | -34.69M | -24.88M |
| IssuanceOfDebt | 34.89M | 54.03M | 0.00 | 0.00 |
| IssuanceOfCapitalStock | 0.00 | 44.39M | 26.32M | |
| CapitalExpenditure | -1.88M | -8.14M | -2.21M | -1.30M |
| EndCashPosition | 14.77M | 19.24M | 20.81M | 11.49M |
| BeginningCashPosition | 19.24M | 20.81M | 11.49M | 10.85M |
| ChangesInCash | -4.47M | -1.57M | 9.32M | 639.00K |
| FinancingCashFlow | 34.96M | 53.99M | 44.02M | 25.52M |
| CashFlowFromContinuingFinancingActivities | 34.96M | 53.99M | 44.02M | 25.52M |
| NetOtherFinancingCharges | -61.00K | -43.00K | -500.00K | -1.41M |
| ProceedsFromStockOptionExercised | 130.00K | 5.00K | 125.00K | 613.00K |
| NetCommonStockIssuance | 0.00 | 44.39M | 26.32M | |
| CommonStockIssuance | 0.00 | 44.39M | 26.32M | |
| NetIssuancePaymentsOfDebt | 34.89M | 54.03M | 0.00 | 0.00 |
| NetLongTermDebtIssuance | 34.89M | 54.03M | 0.00 | 0.00 |
| LongTermDebtIssuance | 34.89M | 54.03M | 0.00 | 0.00 |
| InvestingCashFlow | -1.88M | -8.13M | -2.21M | -1.30M |
| CashFlowFromContinuingInvestingActivities | -1.88M | -8.13M | -2.21M | -1.30M |
| NetPPEPurchaseAndSale | -1.88M | -8.13M | -2.21M | -1.30M |
| SaleOfPPE | 0.00 | 10.00K | 0.00 | |
| PurchaseOfPPE | -1.88M | -8.14M | -2.21M | -1.30M |
| OperatingCashFlow | -37.55M | -47.42M | -32.48M | -23.57M |
| CashFlowFromContinuingOperatingActivities | -37.55M | -47.42M | -32.48M | -23.57M |
| InterestPaidCFO | 0.00 | -586.00K | ||
| ChangeInWorkingCapital | -2.10M | -9.65M | 439.00K | -3.22M |
| ChangeInOtherWorkingCapital | 3.64M | 499.00K | ||
| ChangeInOtherCurrentLiabilities | -4.96M | -13.45M | 3.64M | |
| ChangeInPayablesAndAccruedExpense | -2.24M | -1.02M | 4.46M | 656.00K |
| ChangeInAccruedExpense | 1.51M | -1.06M | 793.00K | 472.00K |
| ChangeInPayable | -3.75M | 39.00K | 3.67M | 184.00K |
| ChangeInAccountPayable | -3.75M | 39.00K | 3.67M | 184.00K |
| ChangeInPrepaidAssets | 5.11M | 4.83M | -7.66M | -1.95M |
| ChangeInReceivables | 1.05M | -2.43M | ||
| OtherNonCashItems | -18.59M | 25.41M | 60.00K | |
| StockBasedCompensation | 2.89M | 938.00K | 3.10M | 2.88M |
| DepreciationAmortizationDepletion | 1.32M | 972.00K | 892.00K | 1.17M |
| DepreciationAndAmortization | 1.32M | 972.00K | 892.00K | 1.17M |
| Depreciation | 892.00K | 1.17M | ||
| OperatingGainsLosses | -2.17M | 3.94M | -722.00K | |
| GainLossOnSaleOfPPE | 0.00 | 81.00K | 0.00 | |
| NetIncomeFromContinuingOperations | -18.92M | -69.05M | -36.92M | -23.16M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for ARMP
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|